INTRODUCTION {#s1}
============

Bladder cancer is the ninth most commonly diagnosed cancer worldwide and ranks second in terms of incidence among genitourinary malignancies. The American Cancer Society estimated that in the United States there were 76,960 new cases and 16,390 mortalities from bladder cancer in 2016 \[[@R1]\]. A trend of increasing incidence and mortality rates has been observed in the past three decades. Radical cystectomy (RC) is the standard treatment for muscle-invasive bladder cancer and non-muscle-invasive bladder cancers with high-risk features \[[@R2]\]. Although minimally invasive techniques have increased in application, with the goal of minimizing patient mortality, the mortality associated with bladder cancer following RC has not changed substantially in the last 30 years \[[@R3]\]. Research regarding the effects of risk factors on the survival outcomes of bladder cancer following treatment with RC remains important. Currently, the stage and grade of tumors are used as the major prognostic factors for these patients \[[@R3]\]. However, there is growing interest in identifying additional prognostic indicators to aid medical professionals in improving prognostic evaluation.

Surgical margin status is determined by the presence or absence of tumor tissue in the areas of soft tissue around the surgical specimen. Although the potential associations between surgical margin status and survival outcome have received much attention in the past few years, studies have yielded inconsistent results. Several large retrospective studies have demonstrated that positive surgical margins are an independent predictor of recurrence and eventual mortality from bladder cancer \[[@R4]--[@R6]\]. On the contrary, other studies demonstrated that positive surgical margins were not independently associated with the risk of local recurrence or the disease-free survival of bladder cancer patients after RC, indicating that surgical margin status may not be a significant factor in determining the eventual prognosis compared with other widely accepted prognostic indicators \[[@R7]--[@R9]\]. To date, no quantitative assessment concerning the association of surgical margin status with outcomes in bladder cancer following treatment with RC has been conducted.

In the present study, a meta-analysis was conducted to summarize the relationship between surgical margin status and bladder cancer outcome after RC based on all published epidemiological studies. The purpose of this meta-analysis was to clarify the association between surgical margin status and survival outcomes of RC, and explore potential sources of heterogeneity across different studies.

RESULTS {#s2}
=======

Search results {#s2_1}
--------------

Figure [1](#F1){ref-type="fig"} illustrates the process of the literature search. Briefly, a total of 2,761 articles were identified using our search strategy, of which 250 were considered potentially relevant articles after excluding duplicate articles and screening the titles and abstracts. A further 141 articles were excluded because that they did not evaluate margin status, or did not focus on survival outcomes. After assessing the remaining 109 articles by full-text review, 73 articles were excluded; of these, 24 articles did not investigate the associations between surgical margin status and survival outcomes of bladder cancer in patients who had undergone RC, 32 were excluded because they did not report relative risk estimates and the corresponding 95% CI or did not provide the sufficient data to calculate them, and 17 articles were excluded as the participants overlapped with other studies. Finally, a total of 36 articles were included in the meta-analysis. The outcomes used were recurrence-free survival (RFS) in 16 studies, cancer-specific survival (CSS) in 26 studies and overall survival (OS) in 18 studies.

![Flow chart illustrating the study selection](oncotarget-08-17258-g001){#F1}

Characteristics of the included studies {#s2_2}
---------------------------------------

The main characteristics of the included studies are shown in Table [1](#T1){ref-type="table"}. All studies were published between 2004 and 2015, with the mean duration of follow-up varying from 20 to 148 months. Of the 36 studies, 14 were conducted in North America \[[@R4], [@R8]--[@R20]\], 8 in Europe \[[@R21]--[@R28]\], 6 in Asia \[[@R7], [@R29]--[@R33]\] and 8 at international multicenters \[[@R34]--[@R41]\]. The meta-analysis was based on a total sample size of 38,384 patients, of which 4,354 patients were reported to have positive surgical margins. Regarding tumor stage, 19,377 patients presented with organ-confined disease and 18,669 with non-organ confined disease. The majority of the included studies were limited to urothelial bladder carcinoma, while 12 studies involved other tumor types, including squamous cell carcinoma, adenocarcinoma and small cell carcinoma. In addition, there were 5 studies \[[@R11], [@R14], [@R15], [@R20], [@R29]\] in which the histopathological types were not described.

###### Characteristics of studies included in meta-analysis of surgical margin status and bladder cancer outcomes

  Study                            Country/Type                       Period      Mean follow -up(months)   Mean age   Sample-size   Positive SM(%)   Positive LN(%)   T stage(%)
  -------------------------------- ---------------------------------- ----------- ------------------------- ---------- ------------- ---------------- ---------------- --------------------
  Soave 2015 \[[@R21]\]            Germany; single-center study       1996-2011   45.0                      67.0       517           12.0             26.7             ≤T2:55.5; ≥T3:44.5
  Satkunasivam 2015 \[[@R10]\]     USA; single-center study           1971-2009   148.8                     66.2       2047          0.0              NA               ≤T2:63.3; ≥T3:36.7
  Reder 2015 \[[@R8]\]             USA; single-center study           2000-2012   20.0                      67.9       364           10.7             20.0             ≤T2:54.1; ≥T3:44.5
  Raza 2015 \[[@R34]\]             International multicenter study    2003-2015   67.0                      69.0       702           8.0              21.0             ≤T2:62.0; ≥T3:38.0
  Kanatani 2015 \[[@R29]\]         Japan; single-center study         1990-2012   29.0                      64.0       61            11.5             50.8             ≤T2:13.1; ≥T3:86.9
  Gakis 2015 \[[@R35]\]            International multicenter study    1994-2011   64.0                      54.0       297           2.4              20.2             ≤T2:40.4; ≥T3:59.6
  Booth 2015 \[[@R11]\]            Canada; single-center study        1994-2008   NA                        72.0       2802          13.0             29.0             ≤T2:29.0; ≥T3:71.0
  Aziz 2015 \[[@R36]\]             International multicenter study    1989-2011   40.0                      68.0       856           24.8             53.6             ≤T2:0.0; ≥T3:100.0
  Albisinni 2015 \[[@R22]\]        International multicenter study    2000-2013   50.0                      68.0       503           5.8              23.1             ≤T2:57.9; ≥T3:42.1
  Yuh 2014 \[[@R12]\]              USA; single-center study           2004-2012   52.0                      70.0       162           4.3              21.6             ≤T2:66.7; ≥T3:33.3
  Suer 2014 \[[@R30]\]             Turkey; single-center study        1990-2012   37.7                      66.5       290           7.6              14.5             ≤T2:54.8; ≥T3:45.2
  Sejima 2014 \[[@R31]\]           Japan; single-center study         2003-2011   24.8                      71.1       249           4.4              15.7             ≤T2:56.6; ≥T3:43.4
  Ploussard 2014 \[[@R37]\]        International multicenter study    1979-2012   32.2                      68.0       8141          23.7             23.7             ≤T2:56.8; ≥T3:43.2
  Nieuwenhuijzen 2014 \[[@R23]\]   Netherlands; single-center study   1990-2006   64.0                      62.3       343           10.0             34.0             ≤T2:52.0; ≥T3:48.0
  May 2014 \[[@R24]\]              International multicenter study    1989-2008   36.0                      67.0       385           22.3             51.4             ≤T2:0.0; ≥T3:100.0
  Lin 2014 \[[@R12]\]              USA; single-center study           1990-2010   66.0                      68.0       196           0.0              NA               ≤T2:100.0; ≥T3:0.0
  Kluth 2014 \[[@R38]\]            International multicenter study    1998-2010   36.1                      67.0       2895          5.5              26.9             ≤T2:53.9; ≥T3:46.1
  Klatte 2014 \[[@R39]\]           International multicenter study    1979-2012   41.0                      67.5       7906          5.3              23.8             ≤T2:58.1; ≥T3:41.9
  Bruins 2014 \[[@R25]\]           Netherlands; single-center study   1998-2011   75.6                      65.0       245           2.9              NA               ≤T2:64.9; ≥T3:35.1
  Bachir 2014 \[[@R14]\]           Canada; multicenter study          1998-2008   39.0                      65.6       847           10.6             22.4             ≤T2:49.8; ≥T3:50.2
  Lotan 2013 \[[@R9]\]             USA; single-center study           2007-2012   20.0                      70.0       216           7.0              25.0             ≤T2:60.0; ≥T3:40.0
  Fritsche 2013 \[[@R26]\]         Germany; multicenter study         2006-2010   20.0                      69.0       158           26.6             100.0            ≤T2:19.6; ≥T3:80.4
  Todenhofer 2012 \[[@R27]\]       Germany; single-center study       1999-2010   30.0                      67.8       258           10.1             27.1             ≤T2:50.4; ≥T3:49.6
  Mitra 2012 \[[@R15]\]            USA; single-center study           1971-2005   31.2                      62.3       447           7.8              48.8             ≤T2:26.6; ≥T3:24.6
  Gondo 2012 \[[@R32]\]            Japan; single-center study         2000-2009   26.8                      68.0       194           10.3             10.8             ≤T2:55.7; ≥T3:44.3
  Yafi 2011 \[[@R16]\]             Canada; multicenter study          1998-2008   35.0                      68.0       2287          8.6              25.9             ≤T2:48.1; ≥T3:51.9
  Sonpavde 2011 \[[@R40]\]         International multicenter study    1971-2008   39.4                      68.5       578           4.0              0.0              ≤T2:0.0; ≥T3:100.0
  Hofner 2011 \[[@R28]\]           Germany; single-center study       1990-2009   104.4                     64.0       328           17.0             36.0             ≤T2:49.0; ≥T3:51.0
  Tilki 2010 \[[@R41]\]            International multicenter study    1979-2008   55.0                      68.9       583           24.9             53.5             ≤T2:0.0; ≥T3:100.0
  Kim 2010 \[[@R33]\]              Korea; single-center study         1986-2005   66.3                      60.8       406           3.9              12.1             ≤T2:67.2; ≥T3:32.8
  Fairey 2009 \[[@R17]\]           Canada; single-center study        1994-2007   31.0                      66.0       523           12.0             23.0             ≤T2:49.0; ≥T3:51.0
  Chapman 2009 \[[@R18]\]          USA; single-center study           1996-2006   34.3                      66.4       308           12.7             27.3             ≤T2:49.0; ≥T3:51.0
  Canter 2009 \[[@R19]\]           USA; single-center study           1988-2006   46.4                      65.5       344           11.6             NA               ≤T2:89.0; ≥T3:11.0
  Dotan 2007 \[[@R4]\]             USA; single-center study           1985-2005   NA                        65.9       1589          4.2              24.0             ≤T2:54.0; ≥T3:46.0
  Lee 2006 \[[@R7]\]               Korea; single-center study         1995-2002   37.1                      61.0       115           4.3              0.0              NA
  Herr 2004 \[[@R20]\]             USA; multicenter study             1987-1998   106.8                     64.6       242           10.0             20.5             ≤T2:69.0; ≥T3:31.0

Abbreviations: SM, surgical margin; LN, lymph node; NA, data not applicable

Meta-analysis {#s2_3}
-------------

In 16 studies, with a total sample size of 10,738 individuals, the associations between positive surgical margin and RFS of bladder cancer patients after RC were reported. A fixed effects model was used, revealing a summary relative risk estimate (SRRE) of 1.63 \[95% confidence interval (CI), 1.46-1.83; Figure [2](#F2){ref-type="fig"}\], with no significant heterogeneity found (Q statistic, *P* = 0.105; I^2^ = 32.1%). The pooled result indicated that the presence of positive surgical margins was associated with poor RFS. The CSS was reported in 26 studies that enrolled a total of 25,804 bladder cancer patients. A random effects model was used due to evidence of heterogeneity among the studies (Q statistic, *P* = 0.001; I^2^ = 54.5%). A significant CSS disadvantage was detected in the positive surgical margin group compared with the negative surgical margin group (SRRE, 1.82; 95% CI, 1.63-2.04; Figure [3](#F3){ref-type="fig"}). In addition, patients with positive surgical margins were found to have an increased risk in terms of OS (SRRE, 1.68; 95% CI, 1.58-1.80; Figure [4](#F4){ref-type="fig"}), without evidence of heterogeneity (Q statistic, *P* = 0.805; I^2^ = 0.0%).

![Meta-analysis of studies that examined the association between positive surgical margin and recurrence-free survival (RFS) following radical cystectomy (RC)](oncotarget-08-17258-g002){#F2}

![Meta-analysis of studies that examined the association between positive surgical margin and cancer-specific survival (CSS) following radical cystectomy (RC)](oncotarget-08-17258-g003){#F3}

![Meta-analysis of studies that examined the association between positive surgical margin and overall survival (OS) following radical cystectomy (RC)](oncotarget-08-17258-g004){#F4}

In sensitivity analyses excluding one study at a time, the SRRE for RFS ranged from 1.59 (95% CI, 1.38-1.83) to 1.71 (95% CI, 1.50-1.94). Similarly, the SRRE for CSS ranged from 1.77 (95% CI, 1.60-1.97) to 1.86 (95% CI, 1.65-2.09), and the SRRE for OS ranged from 1.67 (95% CI, 1.55-1.80) to 1.71 (95% CI, 1.59-1.84). These results indicated that the findings were reliable and robust. No statistical evidence of publication bias was found in this meta-analyses, as assessed by Begg's and Egger's tests for RFS (p-Begg = 0.300; p-Egger = 0.442; Figure [5A](#F5){ref-type="fig"}), CSS (p-Begg = 0.252; p-Egger = 0.194; Figure [5B](#F5){ref-type="fig"}) and OS (p-Begg = 0.649; p-Egger = 0.480; Figure [5C](#F5){ref-type="fig"}), respectively.

![Funnel plots for publication bias of the hazard ratios (HRs) of (A) recurrence-free survival (RFS), (B) cancer-specific survival (CSS), and (C) overall survival (OS)](oncotarget-08-17258-g005){#F5}

Test of heterogeneity {#s2_4}
---------------------

Subgroup and meta-regression analyses were conducted to explore the source of heterogeneity according to mean patient age (≥65 *vs*. \< 65), sample size (≥500 *vs*. \< 500), publication year (≥2014 *vs*. \< 2014), duration of follow-up (≥60 months *vs*. \< 60 months), study type (single center *vs*. multicenter) and geographic region (North America, Europe or Asia). Although no significant modifiers accounting for the inter-study heterogeneity were detected, the observed heterogeneity in CSS decreased significantly in some models, such as articles published since 2014, multicenter studies, study with sample size \>500 cases, and with follow-up duration \>60 months. Furthermore, the results in subgroup analyses were consistent with the primary findings (Table [2](#T2){ref-type="table"}).

###### Summary of meta-analysis results for surgical margin status and outcomes of RC

  --------------------------------------------------------------------------------------------------------------------
  Analysis specification     Studies   SRRE (95% CI)      Meta regression *P*-value   Heterogeneity I^2^   *P*-value
  -------------------------- --------- ------------------ --------------------------- -------------------- -----------
  Recurrence-free survival                                                                                 

  All                        16        1.63 (1.46-1.83)                               32.1                 0.105

  Mean age                                                                                                 

  ≥65                        13        1.61 (1.43-1.81)   0.259                       34.8                 0.104

  \<65                       3         2.44 (1.37-4.34)   0.0                         0.419                

  Sample size                                                                                              

  ≥500                       8         1.65 (1.45-1.87)   0.765                       0.0                  0.477

  \<500                      8         1.56 (1.16-2.10)   54.6                        0.031                

  Published year                                                                                           

  ≥2014                      12        1.73 (1.50-1.99)   0.257                       3.4                  0.411

  \<2014                     4         1.45 (1.18-1.78)   65.6                        0.033                

  Mean follow-up                                                                                           

  ≥60                        6         2.26 (1.57-3.23)   0.128                       0.0                  0.857

  \<60                       10        1.57 (1.39-1.78)   46.2                        0.053                

  Study type                                                                                               

  Single-center              9         1.54 (1.21-1.97)   0.624                       43.8                 0.076

  Multicenter                7         1.66 (1.46-1.83)   20.9                        0.270                

  Region                                                                                                   

  America                    6         1.36 (1.07-1.73)   0.160\                      51.0                 0.070
                                                          0.306                                            

  Europe                     4         1.73 (1.29-2.34)   0.0                         0.861                

  Asia                       1         3.20 (1.31-7.82)   /                           /                    

  Cancer-specific survival                                                                                 

  All                        26        1.82 (1.63-2.04)                               54.5                 0.001

  Mean age                                                                                                 

  ≥65                        20        1.79 (1.58-2.02)   0.572                       58.9                 0.000

  \<65                       6         2.00 (1.49-2.68)   36.8                        0.161                

  Sample size                                                                                              

  ≥500                       12        1.74 (1.59-1.91)   0.662                       24.8                 0.200

  \<500                      14        1.94 (1.48-2.54)   67.1                        0.000                

  Published year                                                                                           

  ≥2014                      13        1.70 (1.53-1.89)   0.462                       27.1                 0.171

  \<2014                     13        1.92 (1.54-2.40)   66.2                        0.000                

  Mean follow-up                                                                                           

  ≥60                        4         2.30 (1.72-3.09)   0.475                       0.0                  0.424

  \<60                       20        1.77 (1.54-2.04)   60.3                        0.000                

  Study type                                                                                               

  Single-center              16        2.06 (1.71-2.48)   0.101                       58.4                 0.002

  Multicenter                10        1.63 (1.45-1.84)   34.8                        0.130                

  Region                                                                                                   

  America                    8         1.84 (1.55-2.19)   0.408\                      50.0                 0.051
                                                          0.618                                            

  Europe                     7         1.97 (1.40-2.75)   68.8                        0.004                

  Asia                       6         2.29 (1.46-3.58)                               57.1                 0.040

  Over survival                                                                                            

  All                        18        1.68 (1.58-1.80)                               0.0                  0.805

  Mean age                                                                                                 

  ≥65                        16        1.68 (1.58-1.80)   0.911                       0.0                  0.895

  \<65                       2         1.72 (1.23-2.39)   69.3                        0.071                

  Sample size                                                                                              

  ≥500                       9         1.68 (1.57-1.81)   0.995                       0.0                  0.610

  \<500                      9         1.69 (1.44-1.97)   0.0                         0.693                

  Published year                                                                                           

  ≥2014                      12        1.64 (1.53-1.76)   0.066                       0.0                  0.987

  \<2014                     6         1.95 (1.66-2.28)   0.0                         0.444                

  Mean follow-up                                                                                           

  ≥60                        4         1.88 (1.42-2.49)   0.980                       0.0                  0.434

  \<60                       13        1.65 (1.53-1.79)   0.0                         0.766                

  Study type                                                                                               

  Single-center              10        1.73 (1.57-1.90)   0.474                       0.0                  0.781

  Multicenter                8         1.65 (1.51-1.80)   0.0                         0.563                

  Region                                                                                                   

  America                    11        1.76 (1.61-1.92)   0.531\                      0.0                  0.556
                                                          0.698                                            

  Europe                     3         1.68 (1.31-2.17)   0.0                         0.694                

  Asia                       1         1.52 (1.01-2.42)   /                           /                    
  --------------------------------------------------------------------------------------------------------------------

DISCUSSION {#s3}
==========

RC with urinary diversion is the gold standard treatment for muscle-invasive bladder cancer or high-risk and recurrent superficial bladder cancer. According to a multi-institutional database of 888 bladder cancer patients who underwent RC, the 5-year RFS and CSS rates were 58 and 66%, respectively \[[@R42]\]. However, regarding bladder cancer patients with advanced tumor stage, lymph node involvement, lymphovascular invasion and high tumor grade, \>50% experience systemic relapse and ∼50% develop distant metastases \[[@R43], [@R44]\]. Therefore, identifying further potential predictive markers will be useful for the prognosis and management of bladder cancer patients treated with RC.

To the best of our knowledge, the present study is the first meta-analysis of the association between positive surgical margins and outcomes of bladder cancer treated with RC. Novara G et al \[[@R6]\] had evaluated the prognostic relevance of surgical margin status in a multicentre study of more than 4,400 patients treated with RC. they recommended that surgical margin status should be reported in pathological reports following RC, and should prompt consideration of further adjuvant therapy for the patient. The past few years have seen growing much debate on surgical margin status and outcomes of bladder cancer after RC. However, until a prospective, randomized-controlled study is done, the findings from a meta-analysis of retrospective studies are the best evidence available.

In this analysis, 36 cohort studies were included, with a large sample size of 38,384 bladder cancer patients. This study provided relatively robust evidence demonstrating that the presence of positive surgical margins was associated with poor outcomes in terms of RFS, CSS and OS in bladder cancer patients treated with RC. The SRREs of positive surgical margins, and RFS, CSS and OS were 1.63 (95% CI, 1.46-1.83), 1.82 (95% CI, 1.63-2.04) and 1.68 (95% CI, 1.58-1.80), respectively, compared with negative surgical margins. The findings were consistently independent of age, sample size, publication year, follow-up duration, study type and geographical region. The sensitivity analyses indicated that the findings were reliable and robust. In addition, there was no evidence of significant publication bias in these analyses according to Begg's or Egger's tests.

Heterogeneity is often a major concern in meta-analyses. Significant heterogeneity was detected in the analysis of the CSS model, although there was no evidence of heterogeneity in terms of RFS or OS. Many confounding variables differed across the individual studies, including age, gender, pathological stage and lymph node status; this may explain the observed heterogeneity between the studies. To address the issue of heterogeneity, subgroup analyses were conducted, revealing that the significant variations were reduced in the meta-analysis of article subgroups published since 2014, with a multicenter design, with a sample size \>500 patients and with follow-up duration \>60 months.

Potential risk factors contributing to positive surgical margins are as follows: i) features of advanced cancer, such as lymphovascular invasion, extravesical disease and mixed histology \[[@R4]\]; ii) surgeon-dependent factors, including the type of procedure, technique and experience; and iii) specimen handling and accurate interpretation of RC \[[@R45], [@R46]\]. Due to the significant adverse associations between positive surgical margins and outcomes of bladder cancer after RC, interest in the preventive management of positive surgical margins has arisen. Although intraoperative frozen section analysis of the urethral margin prior to urinary tract reconstruction has been accepted as a standard practice \[[@R47]\], there is much debate concerning its usefulness in determining ureteral and urethral margin status \[[@R8], [@R48]\]. Further research is required to accurately evaluate the costs and benefits of intraoperative frozen section analysis for patients treated by RC.

Several important strengths of the present study should be noted. Firstly, the meta-analysis included 36 studies with a large sample size to detect more stable associations and provide more reliable results. Secondly, strict accordance with the inclusion and exclusion criteria was maintained, and we also extracted available data from relevant studies that mentioned the relationship between surgical margin status and survival outcomes of bladder cancer patients after RC. Furthermore, the results were found to be reliable and robust through subgroup and sensitivity analyses.

However, the study was subject to several limitations. First and foremost, the majority of the included studies were retrospective cohort studies, which made our meta-analysis sensitive to potential confounding variables. Additionally, although the results from the main multivariable model that included the most adjusted confounders were used, there may be residual or unknown confounding variables that were not taken into consideration in the included studies. Secondly, substantial heterogeneity was observed in the meta-analysis of CSS. Although subgroup and meta-regression analyses were conducted to explore the source of heterogeneity, no effect modifier of heterogeneity was found. Thirdly, we were unable to explore the potential differences in associations according to the classification of bladder cancer. It remains unknown whether the findings may vary by tumor subtype or tumor stage, even though some subgroup analyses were conducted. An additional limitation is that the detection methods of surgical margin status were not definitely described in the majority of the included studies. Therefore, a subgroup analysis for detection methods could not be performed. Moreover, other detailed information regarding the features of the margins, such as the location, focality, and microscopic or macroscopic features, were also not presented in the included studies, and could not be further examined.

In summary, the present meta-analysis confirms that bladder cancer patients with positive surgical margins, as compared with negative surgical margins, are likely to have poorer RFS, CSS and OS after RC, indicating that surgical margin status may be an independent indicator of the survival outcome of patients with bladder cancer following RC.

MATERIALS AND METHODS {#s4}
=====================

Search strategy {#s4_1}
---------------

This meta-analysis was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines \[[@R49]\]. A systematic literature search was performed in the Pubmed, Embase and the Cochrane Library databases to identify eligible studies published between the inception of the databases and April 2016. The primary search string included the following items: 'bladder cancer', 'transitional cell carcinoma' or 'urinary bladder neoplasms'; 'margin' or 'margins'; 'surgery' or 'radical cystectomy'. The search was focused on human studies. No additional filters were included to restrict the search. Furthermore, a manual search of the reference lists of relevant review articles was conducted to identify all available studies.

Inclusion and exclusion criteria {#s4_2}
--------------------------------

The eligibility of each study was assessed using the population, intervention, comparator, outcome and study design (PICOS) approach \[[@R49]\]. A study was included in the analysis if it met the following criteria: the bladder cancer patient was treated with RC (P); the surgical margin was assessed by pathologists (I); the oncological outcomes with positive surgical margins were compared with negative surgical margins (C); the results were reported as risk estimates (hazard ratios, risk ratios, odds ratios) with corresponding 95% confidence intervals, or sufficient data was provided to estimate these (O); and the study was a prospective or retrospective cohort design (S).

In addition to these criteria, only studies that reported survival outcomes, such as RFS, CSS or OS, were considered for inclusion. Case-reports, reviews, expert opinions or meeting abstracts without usable data were excluded. In studies with the same or overlapping population, only the most recent and informative study was included in the meta-analysis.

Data extraction {#s4_3}
---------------

Data from all included studies were independently extracted by two investigators and corroborated by another investigator. The following information was extracted for each included study: first author, year of publication, study type, country, study period, duration of follow-up, sample size, mean age, gender, pathological stage, positive lymph node rate, positive surgical margin rate, and risk estimates of RFS, CSS or OS based on margin status. If one study contained multiple data sets, the one with more adjusted confounders was used. All discrepancies in data extraction were resolved by discussion.

Statistical analysis {#s4_4}
--------------------

All included studies used multivariable Cox proportional hazards ratio models to examine the associations between surgical margin status and survival outcomes of RC, including RFS, CSS or OS. SRREs and 95% CIs were calculated in order to compare the positive margin group with the negative margin group. Heterogeneity between studies was assessed using the Q and I^2^ statistics. *P* \< 0.10 or I^2^\>50% were used to indicate heterogeneity. Random effects models were used for meta-analysis in cases of heterogeneity. Forest plots were also applied to assess the relationships between margin status and survival outcomes of bladder cancer treated by RC.

Subgroup and meta-regression analyses were performed to examine potential sources of heterogeneity according to age, sample size, publication year, follow-up duration, study type and geographical region. Sensitivity analyses were conducted to assess the robustness of the results by repeating the meta-analysis after omitting one study at a time. Furthermore, funnel plots were inspected for asymmetry, and Begg's and Egger's tests were used to assess publication bias. All statistical analyses were conducted using STATA 12.0 software (StataCorp LP, College Station, TX, USA). *P* \< 0.05 was considered to be an indicator of significance, except where specifically noted.
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